FDAnews Drug Daily Bulletin

Oct. 29, 2012 | Vol. 9 No. 212

Senate HELP Committee Confronts State Board Over NECC Pharmacy Classification

The Senate Committee on Health, Education, Labor, & Pensions (HELP) is launching a probe of the compounding crisis, asking the Massachusetts pharmacy registrar to explain why New England Compounding Center (NECC) was allowed to operate as a large-scale drug manufacturer. NECC, the compounder blamed for an outbreak of fungal meningitis, was allowed to maintain its business classification as a pharmacy despite past sterility concerns that led to a 2006 consent decree with the Massachusetts Board of Pharmacy, Sen. Tom Harkin (D-Iowa) and 20 other HELP Committee members said in a Thursday letter to James Coffey, the board’s director.
Drug Industry Daily

Register Now
Print This Page
Email This Article
RSS
Archives

House Track-and-Trace Bill Moves to Floor Without Unit-Level Designs House Track-and-Trace Draft Leaves Unit Level Plan to FDA Senators Raise Alarm Over Hospital Pediatric Drug Shortages; FDA on the Case House Track-and-Trace Draft Leaves Unit Level Finagling to the FDA

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.